
Research Supports Efficacy, Safety of Palivizumab Preventing Lower Respiratory Tract Infections by RSV
Palivizumab is a humanized monoclonal antibody approved by the FDA to prevent serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children.



































